Bone drugs' safety doubted

Share this article:
A new U.S. Food and Drug Administration analysis raises questions about long-term effectiveness among women of the widely prescribed osteoporosis drugs known as bisphosphonates.

The safety of the bone-building drugs, which include brands such as Boniva and Reclast, has been a topic of debate. The FDA's analysis found that after three to five years of use, bisphosphonates offer little to no benefit.

FDA reviewers said it's possible long-term use of the drugs could actually weaken bones, leading to adverse events such as femur fractures and esophageal cancer.
Share this article:
close

Next Article in News

More in News

Long-term care providers achieved 15% antipsychotic reduction goal, CMS announces

Long-term care providers achieved 15% antipsychotic reduction goal, ...

Long-term care facilities have reduced antipsychotic medication use by more than 15% through a large-scale initiative, according to a new report from the Centers for Medicare & Medicaid Services. That ...

Proposed Life Safety Code updates encourage more homelike environments

Updated fire safety regulations could encourage more home-like healthcare environments while increasing security to safeguard against wandering, according to a proposed rule announced Monday.

Visitor shot and killed on the grounds of an assisted living community ...

A woman visiting her mother at an assisted living facility in Kansas was gunned down in the parking lot Sunday, in what authorities are describing as a hate crime.